麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Aug 23 2023

Full Issue

Perspectives: There Is A Ridiculous New Attack On Mifepristone; Opill Must Be Economical

Read recent commentaries about drug-cost issues.

Judge James Ho of the U.S. 5th Circuit Court of Appeals wrote an opinion last week that attracted a lot of attention. A three-judge panel that included Ho ruled in favor of further restrictions on access to mifepristone, the abortion pill, which will remain widely available under a Supreme Court order while litigation continues. (Rhonda Garelick, 8/22)

The Food and Drug Administration recently approved Opill, the first over-the-counter access birth control pill, in a monumental and long overdue win for reproductive and public health care. This FDA ruling will significantly expand access to high-quality contraception for folks across the country. However, true access will require affordability, too. (Dana Singiser, 8/23)

The devastating, drug overdose epidemic in the U.S. killed over 105,000 people last year, most from the synthetic opioid fentanyl. But while fentanyl has dominated the headlines, talk in public health circles has shifted to a new illicit drug on the street: xylazine. (Edward Sisco, 8/22)

The Supreme Court recently announced that it will review Purdue Pharma鈥檚 bankruptcy settlement, which would release the company鈥檚 owners, the Sackler family, from future civil liability for the harms they imposed on millions of opioid victims. Some see this as an opportunity to vindicate victims and prevent abusive bankruptcy settlements. That is wrong. (Anthony Casey and Edward Morrison, 8/21)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优